← Eichor
Study identifier: NCT07349212 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies

Condition: Peanut-Induced Anaphylaxis · Peanut Allergy  ·  Sponsor: Ukko Inc

PhasePhase 1/Phase 2
Planned participants40
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersNo

About this study

This study will test a new investigational treatment called UKK-0018. UKK-0018 as an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Development Officer  ·  +1 503 915 1400  ·  sharron@ukko.us

Always discuss trial participation with your own doctor first.

Locations (5)

Royal Prince Alfred HospitalCamperdown, New South Wales, AustraliaNot Yet Recruiting
Flinders Medical CenterBedford Park, South Australia, AustraliaNot Yet Recruiting
The Royal Melbourne HospitalFitzroy, Victoria, AustraliaRecruiting
Fiona Stanley HospitalPerth, Western Australia, AustraliaNot Yet Recruiting
Pacific Clinical Research Network - AucklandTakapuna, Auckland, New ZealandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07349212